A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the effect of oral Bonviva (150mg, monthly) and placebo on
parameters of bone micro-architecture, assessed by CT scan, bone turnover and bone mineral
density. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly,
and measurements will be taken at baseline, and at intervals over 2 years. The anticipated
time on study treatment is 2+ years, and the target sample size is 100-500 individuals.